Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
DHEA vs HT Acne DHEA versus tibolone · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 17 [0.9, 320.37] | 1 study · 50 participants | Very low |
DHEA vs HT Acne DHEA versus ET + P · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | NR | No studies |
DHEA vs control (placebo or no treatment) Side effects (androgenic overall combined with acne) number of events · women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 3.77 [1.36, 10.47] | 5 studies · 250 participants | Moderate |
DHEA vs control (placebo or no treatment) Side effects ‐ androgenic side effects number of events · women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 6.57 [1.37, 31.59] | 1 study · 92 participants | Low |
DHEA vs control (placebo or no treatment) Side effects ‐ acne number of events · women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 2.26 [0.56, 9.02] | 4 studies · 158 participants | Moderate |
Oral DHEA vs control subgrouped by differing routes of administration QoL, wellbeing (change scores) ‐ oral administration · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | 1 study · 66 participants | Very low |
Oral DHEA vs control subgrouped by differing routes of administration QoL, wellbeing (change scores) ‐ intravaginal application · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | 1 study · 107 participants | Very low |
Oral DHEA vs control subgrouped by differing routes of administration Side effects: acne ‐ skin application · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 2.74 [0.1, 74.87] | 1 study · 22 participants | Very low |
Oral DHEA vs control subgrouped by differing routes of administration Side effects: acne ‐ oral administration · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | OR 2.16 [0.47, 9.96] | 3 studies · 136 participants | Very low |
DHEA vs HT QoL, general wellbeing DHEA versus ET · Women in the peri‐ or postmenopausal phase Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase (2015) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Early oral feeding vs delayed oral feeding Postoperative ileus · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | RR 0.47 [0.17, 1.29] | 3 studies · 279 participants | Moderate |
Early oral feeding vs delayed oral feeding Nausea or vomiting or both · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | RR 1.03 [0.64, 1.67] | 4 studies · 484 participants | Moderate |
Early oral feeding vs delayed oral feeding Time to bowel sounds [days] · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | no estimate extracted | 2 studies · 338 participants | Moderate |
Early oral feeding vs delayed oral feeding Time to the passage of flatus [days] · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | no estimate extracted | 3 studies · 444 participants | High |
Early oral feeding vs delayed oral feeding Time to the first solid diet [days] · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | no estimate extracted | 2 studies · 301 participants | Moderate |
Early oral feeding vs delayed oral feeding Time to first passage of stool [days] · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | no estimate extracted | 2 studies · 249 participants | Moderate |
Early oral feeding vs delayed oral feeding Hospital stay [days] · Women who had major abdominal gynaecologic surgery Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic… (2014) · Cochrane | no estimate extracted | 4 studies · 484 participants | Moderate |
Laparoscopic myomectomy vs open myomectomy (all types) Postoperative pain at 6 hours VAS from 0 to 10 · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | no estimate extracted | 1 study · 148 participants | Moderate |
Laparoscopic myomectomy vs open myomectomy (all types) Postoperative pain at 24 hours VAS from 0 to 10 · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | no estimate extracted | 4 studies · 232 participants | Moderate |
Laparoscopic myomectomy vs open myomectomy (all types) Postoperative pain at 48 hours VAS from 0 to 10 · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | no estimate extracted | 2 studies · 80 participants | Moderate |
Laparoscopic myomectomy vs open myomectomy (all types) Perioperative in‐hospital adverse events; unscheduled return to theatre · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | OR 3.04 [0.12, 75.86] | 2 studies · 188 participants | Low |
Laparoscopic myomectomy vs open myomectomy (all types) Perioperative in‐hospital adverse events; laparoconversion · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | OR 1.11 [0.44, 2.83] | 8 studies · 756 participants | Moderate |
Laparoscopic myomectomy vs open myomectomy (all types) Perioperative in‐hospital adverse events; injury to pelvic organs · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | OR 3.04 [0.12, 75.86] | 1 study · 148 participants | Moderate |
Laparoscopic myomectomy vs open myomectomy (all types) In‐hospital adverse events; postoperative fever · Women with uterine fibroids Minimally invasive surgical techniques versus open myomectomy for uterine fibroids (2014) · Cochrane | OR 0.44 [0.26, 0.77] | 6 studies · 635 participants | Moderate |
Uterine artery embolization (UAE) vs surgery Satisfaction with treatment up to 24 months · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 0.94 [0.59, 1.48] | 6 studies · 640 participants | Moderate |
Uterine artery embolization (UAE) vs surgery Satisfaction with treatment at 5 years · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 0.9 [0.45, 1.8] | 2 studies · 295 participants | Moderate |
Uterine artery embolization (UAE) vs surgery Live birth ‐ UAE versus myomectomy · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 0.26 [0.08, 0.84] | 1 study · 66 participants | Very low |
Uterine artery embolization (UAE) vs surgery Adverse events: intra‐procedural complications · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 0.91 [0.42, 1.97] | 4 studies · 452 participants | Low |
Uterine artery embolization (UAE) vs surgery Adverse events: minor post‐procedural complications within one year · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 1.99 [1.41, 2.81] | 6 studies · 735 participants | Moderate |
Uterine artery embolization (UAE) vs surgery Adverse events: major post‐procedural complications within one year · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 0.65 [0.33, 1.26] | 5 studies · 611 participants | Moderate |
Uterine artery embolization (UAE) vs surgery Further interventions within 2 years · women with symptomatic uterine fibroids Uterine artery embolization for symptomatic uterine fibroids (2014) · Cochrane | OR 3.72 [2.28, 6.04] | 6 studies · 732 participants | Moderate |
Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment Intervention · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | NR | No studies |
Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment Loop ligation of myoma pseudocapsule plus vasopressin · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 70 participants | Low |
Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment Fibrin sealant patch (collagen sponge with thrombin and fibrinogen) · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 70 participants | Low |
Misoprostol vs placebo to reduce blood loss during myomectomy Blood loss (ml) Estimated blood loss during myomectomy · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 2 studies · 89 participants | Moderate |
Misoprostol vs placebo to reduce blood loss during myomectomy Need for blood transfusion Number of participants who received blood transfusion · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | OR 0.36 [0.05, 2.5] | 2 studies · 89 participants | Low |
Misoprostol vs placebo to reduce blood loss during myomectomy Duration of surgery (min) Operative time · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | MD 9 | 1 study · 25 participants | Low |
Vasopressin vs placebo to reduce blood loss during myomectomy Blood loss (ml) Estimated blood loss during myomectomy · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 3 studies · 128 participants | Moderate |
Vasopressin vs placebo to reduce blood loss during myomectomy Need for blood transfusion Participants who received blood transfusion · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | OR 0.15 [0.03, 0.74] | 2 studies · 90 participants | Moderate |
Vasopressin vs placebo to reduce blood loss during myomectomy Duration of surgery Operative time · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 2 studies · 108 participants | Moderate |
Bupivicaine plus epinephrine vs placebo to reduce blood loss during myomectomy Blood loss (ml) Estimated blood loss during myomectomy · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Bupivicaine plus epinephrine vs placebo to reduce blood loss during myomectomy Need for blood transfusion Participants who received blood transfusion · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | NR | No studies |
Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment Misoprostol in abdominal myomectomy · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 25 participants | Moderate |
Bupivicaine plus epinephrine vs placebo to reduce blood loss during myomectomy Duration of surgery (min) Operative time · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Peri‐cervical tourniquet vs no treatment to reduce blood loss during myomectomy Blood loss (ml) Estimated blood loss during myomectomy · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 2 studies · 121 participants | Low |
Peri‐cervical tourniquet vs no treatment to reduce blood loss during myomectomy Need for blood transfusion Participants who received blood transfusion · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | OR 0.22 [0.09, 0.55] | 2 studies · 121 participants | Low |
Peri‐cervical tourniquet vs no treatment to reduce blood loss during myomectomy Duration of surgery (min) Operative time · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Gelatin‐thrombin matrix vs placebo or no treatment to reduce blood loss during myomectomy Blood loss (ml) Estimated blood loss during myomectomy · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Gelatin‐thrombin matrix vs placebo or no treatment to reduce blood loss during myomectomy Need for blood transfusion Participants who received blood transfusion · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | OR 0.01 [0, 0.1] | 1 study · 50 participants | Low |
Gelatin‐thrombin matrix vs placebo or no treatment to reduce blood loss during myomectomy Duration of surgery (min) Operative time · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | MD 5 [1.29, 8.71] | 1 study · 50 participants | Low |